Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Psychosis and/or OCD with Immune Involvement
2024-518391-31-00Phase 2Authorised
- Sponsor
- Region Uppsala
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in obsessive compulsive disorder (OCD), schizophrenia, delusional disorder and 3 more (2 arms), sponsored by Region Uppsala. Primary endpoint: Change in BPRS from baseline to 8 months. Planned start Nov 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
obsessive compulsive disorder (OCD)schizophreniadelusional disorderbrief psychotic disorder (BPD)schizoaffective disorder
Beyond the preview
Go deeper on 2024-518391-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518391-31-00.